本文選題：腸易激綜合征 + 有益菌種��； 參考：《新疆醫(yī)科大學》2014年碩士論文

【摘要】：目的：探討益生菌治療腸易激綜合征(IBS)的臨床療效及安全性。方法：計算機檢索PubMed.國際Cochrane中心、Embase.中國生物醫(yī)學文獻數(shù)據(jù)庫、相關期刊論文、萬方數(shù)據(jù)庫、維普數(shù)據(jù)庫,收集益生菌治療IBS的隨機對照試驗(RCT),并手工檢索已獲文獻的參考文獻,由兩位評價者按照納入和排除標準篩選、提取資料并行方法學質(zhì)量評價,采用RevMan5.0軟件對數(shù)據(jù)行Meta分析。結(jié)果：共納入19個RCT,2172例患者,Meta分析結(jié)果顯示：益生菌較安慰劑在改善患者總體癥狀積分[SMD=-0.18,95%CI(-0.28,-0.08),P=0.0006]、腹痛[SMD=-0.13,95%CI(-0.21,-0.04),P=0.003]、腹脹[SMD=-0.15,95%CI(-0.25,-0.05), P=0.004]、排便不適感[SMD=-0.15,95%CI(0.27,-0.02),P=0.02]方面均有顯著意義,在總體生活質(zhì)量[SMD=0.09,95%CI(-0.08,0.25),P=0.30]、不良反應發(fā)生率[RR=0.91,95%CI(0.71,1.16),P=0.45]方面無顯著意義。結(jié)論：目前證據(jù)顯示益生菌制劑能有效改善IBS患者的臨床癥狀,且安全性好,但現(xiàn)有RCT在力法質(zhì)量學以及研究設計上存在一定不足,今后的研究應在菌株、劑量、療程、IBS亞組患者方面進行嚴謹、高質(zhì)量、大樣本長期隨訪的臨床研究予以證實。
[Abstract]:Objective: to investigate the clinical efficacy and safety of probiotics in the treatment of irritable bowel syndrome (IBS). Methods: PubMed. was searched by computer. International Cochrane Center. Chinese Biomedical Literature Database, full text Database of Chinese Journals, Wanfang Database, Wipu Database, Random controlled trial of probiotic treatment of IBS, and manual retrieval of references obtained, According to the inclusion and exclusion criteria, two evaluators were selected to extract the data and evaluate the quality of parallel methodology. The RevMan5.0 software was used to analyze the data row Meta. There was no significant difference in the overall quality of life (SMD-0.09 / 95) and the incidence of adverse reactions (RRR0.91 / 95CI0.71 / 1.16 / P0.45), and there was no significant difference in the overall quality of life (SMD-0.08) and 0.25% (P = 0.30), and there was no significant difference in the incidence of adverse reactions. Conclusion: the current evidence shows that probiotics can effectively improve the clinical symptoms of patients with IBS, and the safety is good, but there are some deficiencies in the quality of force method and the research and design of the existing RCT, the future research should be in the strain, dosage. A rigorous, high-quality, long-term follow-up study was conducted in the IBS subgroup.
【學位授予單位】：新疆醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2014
【分類號】：R574.4

【參考文獻】

相關期刊論文 前4條

1 張芳芹;徐桂芳;鄒曉平;;益生菌和腸易激綜合征[J];國際消化病雜志;2012年01期

2 張蕾;顧芳;白鵬;呂愈敏;;16S rDNA熒光定量PCR法對腸易激綜合征患者腸道目標菌群的分析[J];山東醫(yī)藥;2009年28期

3 潘國宗,魯素彩,柯美云,韓少梅,郭慧平,方秀才;北京地區(qū)腸易激綜合征的流行病學研究:一個整群、分層、隨機的調(diào)查[J];中華流行病學雜志;2000年01期

4 Philippe Ducrotté;Prabha Sawant;Venkataraman Jayanthi;;Clinical trial:Lactobacillus plantarum 299v(DSM 9843)improves symptoms of irritable bowel syndrome[J];World Journal of Gastroenterology;2012年30期

，

本文編號：1778971